The drug company is offering a $2,500 rebate to anyone who gets a treatment for gonarthritis.
That rebate will help pay for a “small-scale trial,” according to a statement.
Gonti’s drug treatment, Zyrtec, costs $300 per month.
The company is also offering a limited trial to help doctors find a better treatment for people with chronic pain.
The trial will run from July 30 to Aug. 7.
The drug is currently in Phase 2 clinical trials.
Gonto said it plans to expand the trial in the future.
“The trials will provide us with the necessary data to develop a treatment plan that will work in a diverse range of patients and provide a treatment option that can be tailored to the unique needs of patients with gonarthrisis, as well as patients with chronic conditions,” Gonto wrote in the statement.
Gonti says its trial is different from the other drug trials in that the drug is being tested in a randomized, controlled trial.
GobiTec is not the first to try Zyrtec, which has been tested in the U.S. and Europe.
In August, Roche announced that it is working on a Phase 3 trial with a drug called Naloxone.
The Pfizer-owned company is the only pharmaceutical company in the world with a license to sell Zyrtenc.
Naloxoone, an opioid overdose antidote, is being developed by a company called Medtronic Inc. The pharmaceutical company is developing a small-dose drug for chronic pain, the company said in a statement, adding that it plans “to release additional information soon” about the trial.
Pfizer will continue to support the Pfizer subsidiary and help fund clinical studies, the statement said.